Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023

Final Pre-Specified Overall Survival Analysis from the Pivotal Phase 3 CLEAR Trial in Patients with Advanced Renal Cell Carcinoma Will Be Featured in an Oral Presentation NUTLEY, N.J., May 23, 2023 /PRNewswire/ — Eisai announced today the presentation of research across various types of…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.